Phase 3Completed
Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT)
A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
- Sponsor
- SFJ Pharmaceuticals, Inc. (Industry)
- Enrollment
- 226 enrolled
- Conditions
- Hemorrhage; Urgent Surgery; Invasive Procedure
- Interventions
- Bentracimab (PB2452) Infusion
- Ages
- adults, older adults
- Registry
- NCT04286438, EUCTR2019-004457-92
Full record on ClinicalTrials.gov
From the registry
This is a multi-center, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab (PB2452) in patients who present with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure. At least 200 patients will be enrolled from approximately 200 centers in North America, Europe, and Asia-Pacific regions, including mainland China. Patients with reported use of ticagrelor within the prior 3 days who require urgent ticagrelor reversal will be eligible for enrollment. These populations will be enrolled based on separate inclusion criteria.
Primary outcomes
- Reversal - Platelet Reactivity Units (PRU)
- Hemostasis - Uncontrolled major of life-threatening bleeding - Achievement
- Hemostasis - Urgent surgery or invasive procedure - Achievement
History
Last registry update
Primary completion
Started
Registered